JP2017509628A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509628A5
JP2017509628A5 JP2016556898A JP2016556898A JP2017509628A5 JP 2017509628 A5 JP2017509628 A5 JP 2017509628A5 JP 2016556898 A JP2016556898 A JP 2016556898A JP 2016556898 A JP2016556898 A JP 2016556898A JP 2017509628 A5 JP2017509628 A5 JP 2017509628A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
insr
disorder
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016556898A
Other languages
English (en)
Japanese (ja)
Other versions
JP6712230B2 (ja
JP2017509628A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/019362 external-priority patent/WO2015138278A1/en
Publication of JP2017509628A publication Critical patent/JP2017509628A/ja
Publication of JP2017509628A5 publication Critical patent/JP2017509628A5/ja
Application granted granted Critical
Publication of JP6712230B2 publication Critical patent/JP6712230B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016556898A 2014-03-11 2015-03-09 リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 Active JP6712230B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461950960P 2014-03-11 2014-03-11
US61/950,960 2014-03-11
PCT/US2015/019362 WO2015138278A1 (en) 2014-03-11 2015-03-09 Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020094831A Division JP2020147583A (ja) 2014-03-11 2020-05-29 リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法

Publications (3)

Publication Number Publication Date
JP2017509628A JP2017509628A (ja) 2017-04-06
JP2017509628A5 true JP2017509628A5 (enExample) 2018-04-05
JP6712230B2 JP6712230B2 (ja) 2020-06-17

Family

ID=52682963

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016556898A Active JP6712230B2 (ja) 2014-03-11 2015-03-09 リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
JP2020094831A Pending JP2020147583A (ja) 2014-03-11 2020-05-29 リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020094831A Pending JP2020147583A (ja) 2014-03-11 2020-05-29 リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法

Country Status (4)

Country Link
US (3) US20170065678A1 (enExample)
EP (1) EP3125921B1 (enExample)
JP (2) JP6712230B2 (enExample)
WO (1) WO2015138278A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34346A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
US11365228B2 (en) 2017-07-06 2022-06-21 Yale University Mutant FGF21 polypeptide compositions
CN111601613A (zh) * 2017-12-22 2020-08-28 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
EP3586860A1 (en) * 2018-06-22 2020-01-01 Universität Ulm Complement inhibitors and uses thereof
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
CN1678734B (zh) * 2002-06-27 2012-12-12 韦尔瓦制药有限公司 分化调节试剂及其应用
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
PT1641483E (pt) 2003-06-12 2008-04-29 Lilly Co Eli Proteínas de fusão
CA2544602A1 (en) * 2003-11-04 2005-05-26 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
AU2004303783A1 (en) 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1722778A1 (en) * 2004-01-29 2006-11-22 Applied Research Systems ARS Holding N.V. Methods and compositions for the treatment of lipodystrophy
PL1751184T3 (pl) 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
US20110034373A1 (en) 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
US20110015345A1 (en) 2008-03-19 2011-01-20 Ambrx, Inc. Modified FGF-23 Polypeptides and Their Uses
MX2010013333A (es) 2008-06-04 2011-04-05 Amgen Inc Mutantes fgf21 y usos de los mismos.
EA032727B1 (ru) 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
KR20110117666A (ko) 2009-01-23 2011-10-27 노보 노르디스크 에이/에스 알부민 바인더 ａ-ｂ-ｃ-ｄ-ｅ-를 갖는 ｆｇｆ21 유도체 및 그것의 사용
WO2011089170A2 (en) 2010-01-22 2011-07-28 Novo Nordisk A/S Process for preparing fgf-21 with low degree of o-glycosylation
TWI560197B (en) 2009-05-05 2016-12-01 Amgen Inc Fgf21 mutants and uses thereof
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
WO2011154349A2 (en) 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
CN102656266B (zh) 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 具有改变的受体特异性的嵌合成纤维细胞生长因子
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2359843A1 (en) 2010-01-21 2011-08-24 Sanofi Pharmaceutical composition for treating a metabolic syndrome
JP2013523184A (ja) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
EP2595647A1 (en) 2010-07-20 2013-05-29 Novo Nordisk A/S N-terminal modified fgf21 compounds
EP2619226B1 (en) 2010-09-22 2018-09-12 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2012059873A2 (en) 2010-11-05 2012-05-10 Covx Technologies Ireland, Ltd. Anti-diabetic compounds
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
EP2392927A1 (en) * 2011-03-11 2011-12-07 F. Hoffmann-La Roche AG Diagnosis of metabolic disorders in HIV infected patients
US20140294820A1 (en) 2011-06-24 2014-10-02 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2750695A2 (en) * 2011-08-31 2014-07-09 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
UY34346A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
CA2880929A1 (en) 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
WO2015148708A1 (en) 2014-03-25 2015-10-01 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016048999A2 (en) 2014-09-23 2016-03-31 Salk Institute For Biological Studies Fgf21 truncations and mutants and uses thereof
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos

Similar Documents

Publication Publication Date Title
GT201600263A (es) Ácidos grasos novedosos y su uso en la conjugación con biomoléculas
JP6379300B2 (ja) ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途
HRP20211575T1 (hr) Fuzijski proteini za liječenje metaboličkih poremećaja
Hassan et al. Evolution and clinical translation of drug delivery nanomaterials
CY1123307T1 (el) Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
JP2014526441A5 (enExample)
JP2017519739A5 (enExample)
JP2011512856A5 (enExample)
WO2013009545A8 (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
JP2014500880A5 (enExample)
JP2016532690A5 (enExample)
AR083920A1 (es) Metodos de tratamiento de trastornos asociados con el fgf21 (factor de crecimiento de fibroblastos 21)
JP2014530220A5 (enExample)
BR112014032526A2 (pt) composto, e composição farmacêutica
JP2016503770A5 (enExample)
EA200800881A1 (ru) Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами
WO2016060517A3 (ko) 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제
JP2017531613A5 (enExample)
BR112013030067A2 (pt) "conjugado polipeptídico, composição farmacêutica compreendendo o referido conjugado e uso do mesmo"
JP2017512194A5 (enExample)
WO2016109823A8 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
JP2010500284A5 (enExample)
BR112022012499A2 (pt) Peptídeo, composição, métodos para tratar um paciente e para tratar uma doença, e, uso de um peptídeo
JP2017514829A5 (enExample)
Maksimov et al. Possibilities of placentary medicine in restoration treatment